FDA review spotlights risk of heart inflammation linked to Novavax's Covid vaccine — shares tumble

John Carroll

Editor & Founder

Shares of Novavax $NVAX cratered after the FDA’s briefing papers hit Friday morning spelling out concerns about potential heart safety issues with their long-awaited Covid …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA review spotlights risk of heart inflammation linked to Novavax's Covid vaccine — shares tumble

John Carroll

Editor & Founder

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

FDA re­view spot­lights risk of heart in­flam­ma­tion linked to No­vavax's Covid vac­cine — shares tum­ble

Editor & Founder

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

FDA review spotlights risk of heart inflammation linked to Novavax's Covid vaccine — shares tumble